I think we go back to the same cycle. There's funding under CIHR for academic research, and there's a lot of innovative work on academic research in different centres in Canada, but right now there's no mechanism. It's not really that there is reduced funding; there is no practical mechanism that can work for those innovators to take their products from the university setting into development and into a spin-out company. If you want to start a new business with a new antibiotic, and you want to take it into the market eventually, there needs to be a funding mechanism.
For example, private investments right now have dried up. People look at the antibiotic market and see that it doesn't really pay for their investment. They could spend even $2 billion or $3 billion—the figures for antibiotics—and not see that return in their investment. Why would they invest in that space? That's why government intervention is so important.